<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189332</url>
  </required_header>
  <id_info>
    <org_study_id>1527-852A</org_study_id>
    <nct_id>NCT00189332</nct_id>
  </id_info>
  <brief_title>Use of 852A in Metastatic Cutaneous Melanoma.</brief_title>
  <official_title>Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week
      for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessing antitumor activity of 852A intravenous bolus injection administered 3 times a week for 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the safety of the dosage regiment over 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to obtain preliminary data regarding the safety and long term efficacy of 852A in subjects treated with the drug for more than 12 weeks</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Melanoma</condition>
  <condition>Unresectable Metatstatic Cutaneous Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>852A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced melanoma not responding to 1st line chemotherapy

          -  Histological evidence of melanoma

          -  Measurable disease according to RECIST criteria

          -  ECOG performance status less than or equal to 2

          -  Life expectancy 6 months or more

          -  Normal organ and bone marrow function as defined by hematological and serum chemistry
             limits

          -  Adequate contraception for females of childbearing potential

        Exclusion Criteria:

          -  Stage IV disease which has previously progressed during interferon treatment.

          -  Restriction of some therapies/medications for a certain timeframe prior to enrollment
             and during the study including: investigational drugs, high dose corticosteroids,
             immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong
             QT interval and/or induce Torsades De Pointes

          -  History of uncontrolled seizure disorders

          -  Uncontrolled coagulation disorders.

          -  History or evidence of myocardial ischemia, congestive heart failure or arrythmias
             requiring treatment in the past 6 months

          -  History of uncontrolled intercurrent or chronic illness

          -  Concurrent malignancies.

          -  Brain metastases.

          -  HIV positive.

          -  Prolonged QTc interval

          -  Uncontrolled intercurrent or chronic illnesses.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu, 1, Pace de l' Hôpital,</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ste Marguerite,Service de Dermatologie</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik, Medizinische Einrichtungen der Heinrich-Heine - Universität Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie und Venerologie Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(DKFZ) an der Universitäts-Hautklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Hautkrankheiten</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 24, 2008</last_update_submitted>
  <last_update_submitted_qc>October 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

